Tyrosine kinase receptors, drug development

Chemotherapy agents, such as DNA alkylators (see Chapter 6), have traditionally been administered intravenously because of their high chemical reactivity and low bioavailability. During the past decade, a new class of oral anticancer drug, the tyrosine kinase inhibitors, has been developed. These inhibitors bind membrane-bound tyrosine kinase-linked receptors (TKLR) (see Chapter 5). 

---